|
KMID : 1084220190260040221
|
|
Journal of Rheumatic Diseases
2019 Volume.26 No. 4 p.221 ~ p.234
|
|
|
Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors
|
|
Jeung Hei-Cheul
Oh Se-Eung
Kim Jee-Hung
|
|
|
Abstract
|
|
|
|
Recent studies on T cell immunology have been instrumental in developing therapies to overcome cancer immune escape, and immune checkpoint inhibitors have emerged as one of the most promising therapeutic tools in advanced cancer patients. Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that modulate the effects of immune checkpoints. These include cytotoxic T lymphocyte antigen 4 and programmed cell death protein 1, which are co-inhibitory signals responsible for immune suppression. Despite their clinical benefits, ICPIs behave as general immune activators, exerting to several toxic effects called immune-related adverse events attributed to organ-specific inflammation. Here, we review ICPI toxicities, highlighting the importance of their early identification and proper management.
|
|
|
KEYWORD
|
|
|
Immune checkpoint inhibitors, Immune-related adverse events, Adrenal cortex hormones, Programmed cell death protein 1, CTLA-4 antigen
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|